ArticleFrontiers in oncology2026
Histotripsy for multifocal breast cancer liver metastases with early complete metabolic response: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histotripsy is a non-thermal, non-ionizing focused ultrasound therapy that mechanically disrupts tissue through acoustic cavitation. We present a case of a woman with estrogen receptor-positive metastatic breast cancer who developed progressive multifocal liver metastases despite having failed multiple lines of systemic therapies. She underwent two histotripsy treatments staged approximately six weeks apart, using a lobar approach to sequentially treat left- and right-lobe lesions, targeting a total of 10 hepatic lesions. She tolerated both procedures well without any complications or interruption of her targeted therapy (trastuzumab deruxtecan). Follow-up PET/CT performed two months after the second treatment demonstrated complete metabolic response in the liver and overall disease regression, which was again observed on a subsequent PET/CT performed six months later. Follow-up MR imaging four and seven months after the second histotripsy revealed expected post-treatment involution of the treatment zones. This case highlights the ability of histotripsy to treat patients with advanced liver metastases in a staged fashion to minimize potential toxicities. These encouraging early results support the need for more data to confirm the role of histotripsy in advanced metastatic breast cancer patients who have limited treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.